Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FKKG8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,868
Award facts
- Contract value 100% obligated
- $18,868.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc. on December 16, 2025, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected through a firm fixed-price contract with no set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by December 17, 2025, with performance to take place at the vendor's facility in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036. The underlying IDC positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, authorizing DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense medical supply needs globally. The company has demonstrated substantial federal contracting activity and capability across multiple therapeutic categories, including specialty pharmaceuticals and biologics essential to military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FKKG8?
SPE2DR26FKKG8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FKKG8 worth?
The government has obligated $18,868 on SPE2DR26FKKG8.
Is contract SPE2DR26FKKG8 an order under another contract?
Yes. SPE2DR26FKKG8 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKG8 competed?
The extent of competition for SPE2DR26FKKG8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award